MDM2 and Human Malignancies: Expression, Clinical Pathology, Prognostic Markers, and Implications for Chemotherapy
The DOI matches its Crossref record; 182 of the 182 references it cites were found in a registry or an index.
Abstract
The human homologue of the mouse double minute 2 (MDM2) oncogene is overexpressed in more than forty different types of malignancies, including solid tumors, sarcomas and leukemias. Because of its prevalent expression and its interactions with p53 and other signaling molecules, MDM2 plays a central role in cancer development and progression. The expression of this oncoprotein is being studied by researchers world-wide, and the amount of data published about it is increasing exponentially. Although there are some conflicting data about the effects of MDM2 expression in individual cancers, the overall evidence is convincing, indicating that increased MDM2 expression is related to a worse clinical prognosis. There is an increased likelihood of distant metastases, as well as a decreased response to therapeutic intervention in MDM2-positive cancers. MDM2 may also serve as a diagnostic marker, not only for cancer stage, but to differentiate between similar cancers. MDM2 may also be associated with drug resistance in cancer chemotherapy. These findings make studying the oncoprotein necessary to aid in our understanding of cancer development, to identify novel cancer drug targets, and to increase the efficacy of cancer therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Overexpression of Mdm2 is frequently observed in human and murine malignancies (15, 34, 39).”
From Mdm2 Promotes Genetic Instability and Transformation Independent of p53 (2008) · cites this paper as [39]
In the citing paper
“However, MDM2 protein is elevated in 45%–75% of GBM biopsy samples”
From Combination therapy in a xenograft model of glioblastoma: Enhancement of the antitumor activity of temozolomide by an MDM2 antagonist (2017) · cites this paper as [29]
In the citing paper
“Mdm2 is a multi-faceted protein involved in numerous aspects of cell growth, survival, and invasion (6).”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [6]
In the citing paper
“In breast cancers, studies have shown Mdm2 gene amplifications range from 10–60% with some studies indicating a worse prognosis with overexpression of Mdm2 or gene amplification (6, 8).”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [6]
In the citing paper
“In breast cancers, studies have shown Mdm2 gene amplifications range from 10–60% with some studies indicating a worse prognosis with overexpression of Mdm2 or gene amplification (6, 8).”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [6]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760 · cited 1×
“Another group studying neuroblastoma cells documented that loss of p53, including loss by MDM2- induced degradation, resulted in high-level drug resistance to melphalan (L-PAM) [91]. cancers, where HER-2 is overexpressed in an estimated 30% of tumors [97].”
BackgroundIn Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605 · cited 2×
“Another group found that MDM2 was associated with an increase in expression of vascular endothelial growth factor (VEGF), which is known to promote tumor growth and metastasis [10] [66] [67] [68].”
BackgroundRegulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Amplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949 · cited 1×
“…Uterine sarcoma 50% 33% No correlation 12 [190] Angiosarcoma (vascular) 68% Maybe worse 19 [9] Intimal Sarcoma (pulmonary artery) 75% Maybe worse 8 [195] Sarcoma (various) >33% n/a 47 [194] Sarcoma (various) 8% n/a 40 [8] Sarcoma 10% Worse 30 [64] Synovial sarcoma 59% n/a 49 [196] Blood cell…”
Takahashi, Y., Kitadai, Y., Bucana, C. D., Cleary, K. R., & Ellis, L. M. (1995) · PubMed · Cited by 1,265
Bond, G. L., Hu, W., Bond, E. E., Robins, H., Lutzker, S. G., Arva, N. C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.022 · Cited by 1,265
Stott, F. J. (1998) · The EMBO Journal · doi:10.1093/emboj/17.17.5001 · Cited by 1,167 · cited 1×
“MDM2 and p14 have a direct interaction, which inhibits the MDM2-induced degradation of p53 [125] [126].”
BackgroundThe MDM2 gene amplification database
Momand, J. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.15.3453 · Cited by 982
Cited by
Shangary, S., & Wang, S. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094723 · Cited by 623
Ray-Coquard, I., Blay, J.-Y., Italiano, A., Le Cesne, A., Penel, N., Zhi, J., Heil, F., Rueger, R., Graves, B., Ding, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70474-6 · Cited by 571
The MDM2-p53 pathway revisited
Subhasree, N., Jiangjiang, Q., Kalkunte, S., Minghai, W., & Ruiwen, Z. (2013) · The Journal of Biomedical Research · doi:10.7555/jbr.27.20130030 · Cited by 414
“MDM2 overexpression also correlates with metastasis and advanced forms of the disease in osteosarcomas, and cancers of the colon, breast and prostate, and is often associated with more treatment resistant tumors([35]).”
BackgroundSelf-citationMolecular targeting therapies for neuroblastoma: Progress and challenges
Zafar, A., Wang, W., Liu, G., Wang, X., Xian, W., McKeon, F., Foster, J., Zhou, J., & Zhang, R. (2021) · Medicinal Research Reviews · doi:10.1002/med.21750 · Cited by 380
“In general, MDM2 overexpression in human cancers has been found to be correlated to a poor prognosis, and associates with metastasis and advanced stages of the disease.(102) The enhanced MDM2 activity leads to attenuation of p53 activity, and thus results in increased tumor formation.”
BackgroundSelf-citationTargeting the MDM2-p53 Interaction for Cancer Therapy
Shangary, S., & Wang, S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5136 · Cited by 366
Metadata
- Authors
- Rayburn, E., Zhang, R., He, J., & Wang, H.
- Affiliations
- University of Alabama at Birmingham (US)
- Venue
- Current Cancer Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2005-02-01
- Volume
- 5
- Issue
- 1
- Pages
- 27-41
- ISSN
- 1568-0096 (ISSN-L)
- OpenAlex
- W2107368531
- Cited by
- 265
- References
- 172
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 8 · 2023: 15 · 2022: 10 · 2021: 13 · 2020: 15 · 2019: 18 · 2018: 12 · 2017: 24 · 2016: 10 · 2015: 20 · 2014: 19 · 2013: 13 · 2012: 12
- FWCI
- 4.97
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Cancer Drug Targets (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ca080698-04)
- National Cancer Institute (R01CA112029, R01 CA 80698)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- MDM2, p53, oncogene overexpression, prognostic factors, metastasis, chemoresistance, diagnostic biomarkers, cancer drug targets, sarcoma, leukemia, solid tumors, tumor progression
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplasm Metastasis, Neoplasms, Nuclear Proteins, Prognosis, Proto-Oncogene Proteins, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MDM2 and Human Malignancies: Expression, Clinical Pathology, Prognostic Markers, and Implications for Chemotherapy. https://app.cochat.ai/papers/10.2174/1568009053332636
- The paper
- Rayburn, E., Zhang, R., He, J., & Wang, H. (2005). MDM2 and Human Malignancies: Expression, Clinical Pathology, Prognostic Markers, and Implications for Chemotherapy. Current Cancer Drug Targets. https://doi.org/10.2174/1568009053332636
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.